Monthey Resident

DePoly

Cleantech start-up DePoly is behind an innovative solution to the plastics challenge facing the world today.
Based at the Energypolis Campus in Sion and supported by The Ark Foundation, DePoly is now building its demonstration plant on the Monthey chemical site and extending its activities to the BioArk Monthey technology site to follow the construction work.

DePoly Read More »

Regen Lab

Regen Lab’s patented technology revolutionises blood component separation using thixotropic gel. Our kits undergo rigorous biocompatibility and safety testing, and are designed, manufactured, and packaged according to European and international standards.
They meet the requirements of the European Medical Device Directive 93/42/EEC and the European Medical Device Regulation 2017/745.
Regen Lab kits are CE certified and have clearance in multiple countries, including the USA, Canada, Australia, and China.

Regen Lab Read More »

Bioscibex

Bioscibex is at the forefront of biopharmaceutical innovation, providing cutting-edge bioreactor technologies that simplify and automate cell-based therapies. We aim to accelerate and reduce the cost of drug development and manufacturing, making breakthrough treatments accessible to all and improving global health and longevity. Our single-use bioreactor simplifies cell culture with automation and closed system, accommodating volumes from 30 mL to 30 L in the same vessel. It is designed for a broad range of cells. Our technology offers an unmatched scalability (bioreactor’s 1000:1 turndown ratio), advanced sensors, modularity and a proven technology.

Bioscibex Read More »

Ninsun Biotech

Ninsun Biotech is a start-up based in Valais at BioArk. It operates in the field of oncology and is revolutionising the marking of cancer stem cells by offering, for the first time, a specific biomarker for several cancers, including lung, breast and colon. Current technologies rely on the use of a combination of non-specific markers, so Ninsun Biotech is breaking new ground with its patented technology, offering new prospects in terms of diagnosis, monitoring (companion tests) and, ultimately, individualised treatment for patients. Ninsun Biotech’s stem cell marking kits are also perfectly compatible with the current clinical chain of patient management.

Ninsun Biotech Read More »

Scroll to Top